The entire industry agrees on where AI belongs first in a launch. Pfizer already built it, and named it after the man who founded the company. The short version: • Pfizer's Charlie is the clearest real-world proof of the MLR consensus, and it works because it routes risk to humans faster rather than deciding anything itself. • It's the lowest-regret AI win in launch, and worth building. • But the pitch assumes the review was the bottleneck, and the real delay usually sits ups

Every big firm is now selling the same pharma launch. Agentic. Sense-and-respond. "Launch as a learning system." They are all describing the same thing, and none of them is in the room when it fails. The short version: The big-firm launch point of view has converged, and the platforms behind it are real. Launches still drift anyway, because the gap was never structure. It was control. The question isn't which agentic platform to buy. It's who holds the loop closed when the ma